Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

fructooligosaccharide/Lactobacillus paracasei/Lactobacillus rhamnosus/Lactobacillus acidophilus/Bifidobacterium lactis

A synbiotic nutritional supplement containing fructooligosaccharides (FOS), which are linear chains of fructose units that are linked by beta (2-1) bonds, and probiotic cultures of Lactobacillus paracasei (L. paracasei), L. rhamnosus, L. acidophilus and Bifidobacterium lactis (B. lactis), with gastrointestinal (GI) protective and immunomodulating activities. Upon oral administration, the bacteria in this probiotic supplement help maintain adequate colonization of the GI tract and modulate the composition of the normal microflora. Upon colonization of the GI tract, the probiotic bacteria form a protective barrier that helps maintain the integrity of the epithelial barrier. This will interfere with the attachment of pathogenic bacteria and other harmful substances, prevent inflammation and improve GI function. Additionally, the reconstituted microflora may metabolize FOS, which may promote calcium mobilization into the bloodstream by maintaining a neutral pH in the lower gut.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:fructooligosaccharide/L. paracasei/L. rhamnosus/L. acidophilus/B. lactis probiotic supplement
Foreign brand name:LactoFos
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search